MicroDose Therapeutx (formerly MicroDose Technologies Inc) Announces Initiation of Phase 1 Study with Inhaled Atropine as Antidote to Combat Effects of Nerve Agent Poisoning

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has initiated a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI). The study is a further step in the development program for an atropine inhaler to treat nerve agent poisoning in military and civil defense applications. The program is being congressionally funded and managed through the Chemical Biological Medical Systems Joint Project Management Office to treat the symptoms, including bronchopulmonary, of mild to moderate organophosphorus poisoning after adequate amounts of injectable atropine have been administered.